Article
Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial.
Annals of oncology : official journal of the European Society for Medical Oncology - 1 Aug 2018
Corrie P G, Marshall A, Nathan P D, Lorigan P, Gore M, Tahir S, Faust G, Kelly C G, Marples M, Danson S J, Marshall E, Houston S J, Board R E, Waterston A M, Nobes J P, Harries M, Kumar S, Goodman A, Dalgleish A, Martin-Clavijo A, Westwell S, Casasola R, Chao D, Maraveyas A, Patel P M, Ottensmeier C H, Farrugia D, Humphreys A, Eccles B, Young G, Barker E O, Harman C, Weiss M, Myers K A, Chhabra A, Rodwell S H, Dunn J A, Middleton M R, Nathan Paul, Lorigan Paul, Dziewulski Peter, Holikova Sonja, Panwar Udaiveer, Tahir Saad, Faust Guy, Thomas Anne, Corrie Pippa, Sirohi Bhawna, Kelly Charles, Middleton Mark, Marples Maria, Danson Sarah, Lester James, Marshall Ernest, Ajaz Mazhar, Houston Stephen, Board Ruth, Eaton David, Waterston Ashita, Nobes Jenny, Loo Suat, Gray Gill, Stubbings Helen, Gore Martin, Harries Mark, Kumar Satish, Goodman Andrew, Dalgleish Angus, Martin-Clavijo Agustin, Marsden Jerry, Westwell Sarah, Casasola Richard, Chao David, Maraveyas Anthony, Marshall Ernest, Patel Poulam, Ottensmeier Christian, Farrugia David, Humphreys Alison, Eccles Bryony, Dega Renata, Herbert Chris, Price Christopher, Brunt Murray, Scott-Brown Martin, Hamilton Joanna, Hayward Richard Larry, Smyth John, Woodings Pamela, Nayak Neena, Burrows Lorna, Wolstenholme Virginia, Wagstaff John, Nicolson Marianne, Wilson Andrew, Barlow Clare, Scrase Christopher, Podd Timothy, Gonzalez Michael, Stewart John, Highley Martin, Wolstenholme Virginia, Grumett Simon, Goodman Andrew, Talbot Toby, Nathan Kannon, Coltart Robert, Gee Bruce, Gore Martin, Farrugia David, Martin-Clavijo Agustin, Marsden Jerry, Price Christopher, Farrugia David, Nathan Kannon, Coltart Robert, Nathan Kannon, Coltart Robert
Abstract excerpt
Background: Bevacizumab is a recombinant humanised monoclonal antibody to vascular endothelial growth factor shown to improve survival in advanced solid cancers. We evaluated the role of adjuvant bevacizumab in melanoma patients at high risk of recurrence. Patients and methods: Patients with resected AJCC stage IIB, IIC and III cutaneous melanoma were randomised to receive either adjuvant bevacizumab (7.5 mg/kg...
